Navigation Links
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky Notifies Investors with Losses on Their Investment in Incyte Corporation of Class Action Lawsuit and the May 6, 2013 Lead Plaintiff Deadline
Date:4/23/2013

NEW YORK, April 23, 2013 /PRNewswire/ -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Delaware on behalf of investors who purchased Incyte Corporation ("Incyte" or the "Company") (NasdaqGS: INCY) stock between April 26, 2012 and August 1, 2012 (the "Class Period").

(Logo: http://photos.prnewswire.com/prnh/20120409/MM84375LOGO )

For more information, click here: http://zlk.9nl.com/incyte-incy/.  

According to the complaint, Incyte's reported fourth quarter 2011 and first quarter 2012 sales were artificially inflated due to a large number of advanced-stage myelofibrosis patients being prescribed the drug upon FDA approval in November 2011--patients who had been too sick to participate in the clinical trials.

On August 2, 2012, Incyte disclosed that Jakafi sales growth had been much softer during the second quarter of 2012 than investors had been led to expect. Defendants also disclosed that many of the new patients prescribed Jakafi were so sick they would not have been eligible for the Phase III trial. Defendants conceded that while prescriptions to these patients had increased sales revenues, these were not revenues that would continue for the suggested three years on average that defendants claimed, as certain patients died. In response to these disclosures, the price of Incyte stock fell from its August 1, 2012 close of $24.92 per share to close at $19.57 per share on August 2, 2012.

If you suffered a loss in Incyte you have until May 6, 2013 to request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (877) 363-5972, or visit http://zlk.9nl.com/incyte-incy/.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, and Washington, D.C.  The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits.  Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:   
Levi & Korsinsky, LLP
Joseph Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY 10004           
Tel: (212) 363-7500
Toll Free:  (877) 363-5972
Fax: (866) 367-6510
www.zlk.com


'/>"/>
SOURCE Levi & Korsinsky, LLP
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
2. ICBS, Update for Shareholders.
3. NeoStems CEO Letter to Shareholders
4. Monsanto Attempts to Lockout Socially Responsible Shareholder at Annual Meeting
5. SPO Updates Shareholders on 2012 Corporate Strategy
6. SeraCare Shareholders Approve Acquisition by Linden Capital Partners
7. Genesis Biopharma Issues Letter To Shareholders
8. Medical Marijuana Inc. Shareholder Update - PhytoSPHERE Systems, LLC
9. Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
10. Correction: Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
11. Amarantus BioSciences Issues CEO Letter to Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... SILVER SPRING, Md. , June 23, 2016 ... evidence collected from the crime scene to track the criminal ... sick, and the U.S. Food and Drug Administration (FDA) uses ... Sound far-fetched? It,s not. ... whole genome sequencing to support investigations of foodborne illnesses. Put ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... ... , ... In a new case report published today in STEM CELLS Translational ... lymphedema after being treated for breast cancer benefitted from an injection of stem cells ... this debilitating, frequent side effect of cancer treatment. , Lymphedema refers to ...
(Date:6/23/2016)... YORK , June 23, 2016 ... trading session at 4,833.32, down 0.22%; the Dow Jones Industrial ... S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), ... Therapeutics Inc. (NASDAQ: BIND ). Learn more about ...
Breaking Biology Technology:
(Date:6/3/2016)... LONDON , June 3, 2016 /PRNewswire/ ... Transport Management) von Nepal ... ,Angebot und Lieferung hochsicherer geprägter Kennzeichen, einschließlich ... weltweit führend in der Produktion und Implementierung ... an der Ausschreibung im Januar teilgenommen, aber ...
(Date:6/2/2016)... June 2, 2016 Perimeter Surveillance ... Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... will generate revenues of $17.98 billion in 2016. ... Inc, a leader in software and hardware technologies for ...
(Date:5/20/2016)... 20, 2016  VoiceIt is excited to announce ... By working together, VoiceIt and VoicePass ... and VoicePass take slightly different approaches to voice ... security and usability. ... new partnership. "This marketing and technology ...
Breaking Biology News(10 mins):